Psychotropic medication prescribing in assisted living and nursing home residents with dementia after the National Partnership
dc.contributor.author | Coe, Antoinette B. | |
dc.contributor.author | Zhang, Tingting | |
dc.contributor.author | Zullo, Andrew R. | |
dc.contributor.author | Gerlach, Lauren B. | |
dc.contributor.author | Thomas, Kali S. | |
dc.contributor.author | Daiello, Lori A. | |
dc.contributor.author | Varma, Hiren | |
dc.contributor.author | Lo, Derrick | |
dc.contributor.author | Joshi, Richa | |
dc.contributor.author | Shireman, Theresa I. | |
dc.contributor.author | Bynum, Julie P. W. | |
dc.date.accessioned | 2023-01-11T16:24:50Z | |
dc.date.available | 2024-01-11 11:24:48 | en |
dc.date.available | 2023-01-11T16:24:50Z | |
dc.date.issued | 2022-12 | |
dc.identifier.citation | Coe, Antoinette B.; Zhang, Tingting; Zullo, Andrew R.; Gerlach, Lauren B.; Thomas, Kali S.; Daiello, Lori A.; Varma, Hiren; Lo, Derrick; Joshi, Richa; Shireman, Theresa I.; Bynum, Julie P. W. (2022). "Psychotropic medication prescribing in assisted living and nursing home residents with dementia after the National Partnership." Journal of the American Geriatrics Society 70(12): 3513-3525. | |
dc.identifier.issn | 0002-8614 | |
dc.identifier.issn | 1532-5415 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175468 | |
dc.description.abstract | BackgroundThe Centers for Medicare & Medicaid Services implemented the National Partnership to Improve Dementia Care in Nursing Homes (the Partnership) to decrease antipsychotic use and improve care for nursing home (NH) residents with dementia. We determined whether the extent of antipsychotic and other psychotropic medication prescribing in AL residents with dementia mirrored that of long-stay NH (LSNH) residents after the Partnership.MethodsUsing a 20% sample of fee-for-service Medicare beneficiaries with Part D, we conducted a retrospective cohort study including AL and LSNH residents with dementia. The monthly prevalence of psychotropic medication prescribing (antipsychotics, antidepressants, anxiolytics/sedative-hypnotics, anticonvulsants/mood stabilizers, benzodiazepines, and antidementia medications) was examined. We used an interrupted time-series analysis to compare medication prescribing before (July 1, 2010–March 31, 2012) and after (April 1, 2012–December 31, 2017) the Partnership in both settings.ResultsWe identified 107,931 beneficiaries with ≥1 month as an AL resident and 323,766 beneficiaries with ≥1 month as a LSNH resident with dementia, including 1,923,867 person-months and 4,984,405 person-months, respectively. Antipsychotic prescribing declined over the study period in both settings. After the launch of the Partnership, the rate of decline in antipsychotic prescribing slowed in AL residents with dementia (slope change = 0.03 [95% CLs: 0.02, 0.04]) while the rate of decline in antipsychotic prescribing increased in LSNH residents with dementia (slope change = −0.12 [95% CLs: −0.16, −0.08]). Antidepressants were the most prevalent medication prescribed, anticonvulsant/mood stabilizer prescribing increased, and anxiolytic/sedative-hypnotic and antidementia medication prescribing declined.ConclusionsThe federal Partnership to reduce antipsychotic prescribing in NH residents did not appear to affect antipsychotic prescribing in AL residents with dementia. Given the increase in the prescribing of mood stabilizers/anticonvulsants that occurred after the launch of the Partnership, monitoring may be warranted for all psychotropic medications in AL and NH settings. | |
dc.publisher | John Wiley & Sons, Inc. | |
dc.subject.other | Alzheimer disease | |
dc.subject.other | assisted living facilities | |
dc.subject.other | dementia | |
dc.subject.other | nursing homes | |
dc.subject.other | psychotropic drugs | |
dc.title | Psychotropic medication prescribing in assisted living and nursing home residents with dementia after the National Partnership | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Geriatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175468/1/jgs18004_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175468/2/jgs18004-sup-0001-Supinfo.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175468/3/jgs18004.pdf | |
dc.identifier.doi | 10.1111/jgs.18004 | |
dc.identifier.source | Journal of the American Geriatrics Society | |
dc.identifier.citedreference | Maust DT, Strominger J, Kim HM, et al. Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US. JAMA. 2021; 325 ( 10 ): 952 - 961. doi: 10.1001/jama.2021.1195 | |
dc.identifier.citedreference | McCarthy EP, Chang C-H, Tilton N, Kabeto MU, Langa KM, Bynum JPW. Validation of claims algorithms to identify Alzheimer’s disease and related dementias. J Gerontol A Biol Sci Med Sci. 2022; 77 ( 6 ): 1261 - 1271. doi: 10.1093/gerona/glab373 | |
dc.identifier.citedreference | CMS announces partnership to improve dementia care in nursing homes. Centers for Medicare and Medicaid Services. https://www.cms.gov/newsroom/press-releases/cms-announces-partnership-improve-dementia-care-nursing-homes. Accessed April 20, 2022. | |
dc.identifier.citedreference | Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiat. 2015; 72 ( 5 ): 438 - 445. doi: 10.1001/jamapsychiatry.2014.3018 | |
dc.identifier.citedreference | Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294: 1934 - 1943. | |
dc.identifier.citedreference | Data show National Partnership to improve dementia care acheives goals to reduce unneccessary antipsychotic medications in nursing homes. Centers for Medicare and Medicaid Services. https://www.cms.gov/newsroom/fact-sheets/data-show-national-partnership-improve-dementia-care-achieves-goals-reduce-unnecessary-antipsychotic. Accessed April 20, 2022. | |
dc.identifier.citedreference | Harris-Kojetin L, Sengupta M, Lendon JP, Rome V, Valverde R, Caffrey C. Long-term care providers and services users in the United States, 2015-2016. National Center for Health Statistics. Vital Health Stat. 2019; 3 ( 43 ): 1 - 88. | |
dc.identifier.citedreference | Kronhaus A, Fuller S, Zimmerman S, Reed D. Prevalence and medication management of dementia by a medical practice providing onsite care in assisted living. J Am Med Dir Assoc. 2016; 17: 673.e9 - 673.e15. | |
dc.identifier.citedreference | Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff. 2014; 33 ( 4 ): 658 - 666. doi: 10.1377/hlthaff.2013.1255 | |
dc.identifier.citedreference | Kaskie BP, Nattinger M, Potter A. Policies to protect persons with dementia in assisted living: deja vu all over again? Gerontologist. 2015; 55 ( 2 ): 199 - 209. doi: 10.1093/geront/gnu179 | |
dc.identifier.citedreference | The Joint Commission launches new assisted living community accreditation program. The Joint Commission. https://www.jointcommission.org/resources/news-and-multimedia/news/2021/05/the-joint-commission-launches-new-assisted-living-community-accreditation-program/. Accessed October 18, 2021. | |
dc.identifier.citedreference | Thomas KS, Wretman CJ, Sloane PD, et al. To what extent do local nursing home prescribing patterns relate to psychotropic prescribing in assisted living? J Am Med Dir Assoc. 2021; 22 ( 9 ): 1813 - 1818. | |
dc.identifier.citedreference | Gerlach LB, Kales HC, Kim HM, et al. Trends in antipsychotic and mood stabilizer prescribing in long-term care in the U.S.: 2011–2014. J Am Med Dir Assoc. 2020; 21: 1629 - 1635. | |
dc.identifier.citedreference | Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services’ national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med. 2018; 178 ( 5 ): 640 - 647. doi: 10.1001/jamainternmed.2018.0379 | |
dc.identifier.citedreference | Intrator O, Hiris J, Berg K, Miller SC, Mor V. The residential history file: studying nursing home residents’ long-term care histories. Health Serv Res. 2011; 46: 120 - 137. doi: 10.1111/j.1475-6773.2010.01194.x | |
dc.identifier.citedreference | Thomas KS, Dosa D, Gozalo PL, et al. A methodology to identify a cohort of Medicare beneficiaries residing in large assisted living facilities using administrative data. Med Care. 2018; 56 ( 2 ): e10 - e15. doi: 10.1097/mlr.0000000000000659 | |
dc.identifier.citedreference | Grodstein F, Chang C-H, Capuano AW, et al. Identification of dementia in recent Medicare claims data, compared with rigorous clinical assessments. J Gerontol A Biol Sci Med Sci. 2022; 77 ( 6 ): 1272 - 1278. doi: 10.1093/gerona/glab377 | |
dc.identifier.citedreference | Thomas KS, Cornell PY, Zhang W, et al. The relationship between states’ staffing regulations and hospitalizations of assisted living residents. Health Aff. 2021; 40 ( 9 ): 1377 - 1385. doi: 10.1377/hlthaff.2021.00598 | |
dc.identifier.citedreference | CMS’s RAI Version 2.0 Manual, Appendix E. Centers for Medicare and Medicaid Services. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/downloads/MDS202005AppendixE.pdf. Accessed November 17, 2021. | |
dc.identifier.citedreference | Ref: S&C:13-35-NH Advanced Copy: Dementia Care in Nursing Homes: Clarification to Appendix P State Operations Manual (SOM) and Appendix PP in the SOM for F309 – Quality of Care and F329 – Unnecessary Drugs. Centers for Medicare and Medicaid Services. https://www.cms.gov/medicare/provider-enrollment-and-certification/surveycertificationgeninfo/downloads/survey-and-cert-letter-13-35.pdf. Accessed November 17, 2021. | |
dc.identifier.citedreference | USP Medicare Model Guidelines V8.0 with Example Part D Drugs. Updated February 1, 2020. United States Pharmacopeia. https://www.usp.org/health-quality-safety/usp-medicare-model-guidelines. Accessed November 17, 2021. | |
dc.identifier.citedreference | Gerlach LB, Maust DT, Kales HC, et al. Evaluation of antipsychotic reduction efforts among patients with dementia in Veterans Health Administration nursing homes. Am J Psychiatry. 2022; 179: 544 - 552. doi: 10.1176/appi.ajp.21060591 | |
dc.identifier.citedreference | 2010 Census regions and divisions of the United States. US Census Bureau. https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed September 22, 2021. | |
dc.identifier.citedreference | Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011; 64 ( 7 ): 749 - 759. doi: 10.1016/j.jclinepi.2010.10.004 | |
dc.identifier.citedreference | Sun JW, Rogers JR, Her Q, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2015; 55: 1046 - 1051. | |
dc.identifier.citedreference | Dobbs D, Zimmerman S, Carder P, Beeber AS, Palmertree SJ. Staff reports of behavioral expressions of persons with dementia in 250 assisted living communities. Gerontologist. 2022; 62 ( 2 ): 169 - 180. doi: 10.1093/geront/gnab059 | |
dc.identifier.citedreference | Lei L, Samus QM, Thomas KS, Maust DT. Medication costs and use of older Americans in assisted living settings: a nationally representative cross-sectional study. J Gen Intern Med. 2022. Epub ahead of print. doi: 10.1007/s11606-022-07434-3 | |
dc.identifier.citedreference | Devanand DP, Crocco E, Forester BP, et al. Low dose lithium treatment of behavioral complications in Alzheimer’s disease: lit-AD randomized clinical trial. Am J Geriatr Psychiatry. 2022; 30 ( 1 ): 32 - 42. doi: 10.1016/j.jagp.2021.04.014 | |
dc.identifier.citedreference | Gerlach LB, Kales HC. Pharmacological management of neuropsychiatric symptoms of dementia. Curr Treat Options Psychiatry. 2020; 7 ( 4 ): 489 - 507. doi: 10.1007/s40501-020-00233-9 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.